Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/17/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/17/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/13/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
21 |
| 02/13/23 | 8-K | Current report filing |
|
|
4 |
| 02/13/23 | 8-K | Current report filing |
|
|
57 |
| 02/10/23 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
4 | |
| 02/09/23 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
12 | |
| 02/07/23 | EFFECT | Notice of Effectiveness |
|
1 | |
| 02/07/23 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 02/06/23 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |
